Try our beta test site
IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more...

FOLFOX Plus Regorafenib in Patients With Unresectable or Metastatic Esophagogastric Cancer

This study is ongoing, but not recruiting participants.
Sponsor:
Collaborator:
Bayer
Information provided by (Responsible Party):
Memorial Sloan Kettering Cancer Center
ClinicalTrials.gov Identifier:
NCT01913639
First received: July 29, 2013
Last updated: April 19, 2017
Last verified: April 2017
No Study Results Posted on ClinicalTrials.gov for this Study
  Study Status: This study is ongoing, but not recruiting participants.
  Estimated Study Completion Date: July 2018
  Estimated Primary Completion Date: July 2018 (Final data collection date for primary outcome measure)